Bekanntmachung • May 06
Mesa Laboratories, Inc. to Report Q4, 2026 Results on May 27, 2026 Mesa Laboratories, Inc. announced that they will report Q4, 2026 results at 6:00 AM, US Eastern Standard Time on May 27, 2026 Declared Dividend • Apr 08
Third quarter dividend of US$0.16 announced Dividend of US$0.16 is the same as last year. Ex-date: 29th May 2026 Payment date: 15th June 2026 Dividend yield will be 0.7%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 94%. Cash payout ratio: 9%. Bekanntmachung • Apr 03
Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 15, 2026 Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. Recent Insider Transactions • Mar 12
Lead Independent Director recently bought US$253k worth of stock On the 10th of March, Shiraz Ladiwala bought around 4k shares on-market at roughly US$72.23 per share. This transaction amounted to 70% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$190k more in shares than they have sold in the last 12 months. Upcoming Dividend • Feb 20
Upcoming dividend of US$0.16 per share Eligible shareholders must have bought the stock before 27 February 2026. Payment date: 16 March 2026. Payout ratio is on the higher end at 94%, however this is supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of American dividend payers (4.2%). In line with average of industry peers (0.6%). Bekanntmachung • Feb 18
Mesa Laboratories, Inc. Announces Renewed Commitment to Advancing Primary Standard Calibration Technology Through its DryCal Product Line Mesa Laboratories, Inc. announced a renewed commitment to advancing primary standard calibration technology through its DryCal product line, as occupational health and safety professionals confront rising regulatory scrutiny and a generational workforce transition that threatens the integrity of workplace exposure monitoring. Across industries from pharmaceutical manufacturing to construction, worker safety depends on the accuracy of air sampling pumps used to measure exposure to hazardous substances. Those pumps must be calibrated to strict standards set by the Occupational Safety and Health Administration (OSHA) and the National Institute for Occupational Safety and Health (NIOSH), which require calibrator accuracy of +-1%. Yet a growing share of the calibration market relies on secondary standard instruments that can degrade to +-4-20% error at low flow rates, the very conditions most critical to detecting harmful exposures. Mesa's DryCal technology uses a proprietary piston prover, a primary standard that measures gas flow directly from fundamental SI quantities of volume and time. Unlike secondary standards, which derive flow measurements directly from pressure drop, temperature, and gas viscosity assumptions, a primary standard maintains accuracy across its full operating range without depending on environmental conditions or gas-specific properties. If contamination enters the measurement cell, the DryCal's piston stops moving before it can produce an inaccurate reading, a fail-safe design that secondary instruments, which can drift silently when compromised, do not offer. The distinction between primary and secondary standards has taken on new urgency as OSHA has chosen to standardize its own field enforcement operations on Mesa's Defender series calibrators, purchasing more than 120 units in 2025 with additional orders planned for 2026. As part of its commitment to advancing calibration education across the profession, Mesa Labs is partnering with the American Industrial Hygiene Association (AIHA) to present a webinar, "Flow Calibration Essentials for the OHS Professional," featuring Parameshwar alongside Laurence R. Durio, M.S., CIH, a certified industrial hygienist with more than 50 years of experience, including prior service with OSHA enforcement. The session addresses the science behind primary standards, regulatory requirements, and best practices for avoiding sample inspections. A recording is available through the AIHA website. Mesa's Calibration Solutions division continues to invest in education, product innovation, and expanded service capabilities to support occupational health and safety professionals worldwide. The company's mission, Protecting the V vulnerable®?, is reflected in its commitment to ensuring that the instruments behind workplace exposure decisions meet the highest standards of accuracy and defensibility. Reported Earnings • Feb 04
Third quarter 2026 earnings: EPS and revenues exceed analyst expectations Third quarter 2026 results: EPS: US$0.66 (up from US$0.31 loss in 3Q 2025). Revenue: US$65.1m (up 3.6% from 3Q 2025). Net income: US$3.63m (up US$5.31m from 3Q 2025). Profit margin: 5.6% (up from net loss in 3Q 2025). The move to profitability was primarily driven by lower expenses. Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 135%. Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings. Declared Dividend • Jan 11
Second quarter dividend of US$0.16 announced Dividend of US$0.16 is the same as last year. Ex-date: 27th February 2026 Payment date: 16th March 2026 Dividend yield will be 0.8%, which is higher than the industry average of 0.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (10% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability. Bekanntmachung • Jan 08
Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 16, 2026 Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 16, 2026, to shareholders of record at the close of business on February 28, 2026. Upcoming Dividend • Nov 21
Upcoming dividend of US$0.16 per share Eligible shareholders must have bought the stock before 28 November 2025. Payment date: 15 December 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.9%. Lower than top quartile of American dividend payers (4.6%). Higher than average of industry peers (0.5%). Reported Earnings • Nov 07
Second quarter 2026 earnings: EPS exceeds analyst expectations Second quarter 2026 results: EPS: US$0.45 (down from US$0.63 in 2Q 2025). Revenue: US$60.7m (up 5.0% from 2Q 2025). Net income: US$2.48m (down 28% from 2Q 2025). Profit margin: 4.1% (down from 5.9% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 181%. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings. Bekanntmachung • Nov 07
Mesa Laboratories, Inc. Provides Revenue Guidance for the Third Quarter 2026 Mesa Laboratories, Inc. provided revenue guidance for the third quarter 2026. For the quarter, the company expect revenues to sequentially increase. Declared Dividend • Oct 06
First quarter dividend of US$0.16 announced Dividend of US$0.16 is the same as last year. Ex-date: 28th November 2025 Payment date: 15th December 2025 Dividend yield will be 0.9%, which is higher than the industry average of 0.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (11% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability. Upcoming Dividend • Aug 22
Upcoming dividend of US$0.16 per share Eligible shareholders must have bought the stock before 29 August 2025. Payment date: 15 September 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.9%. Lower than top quartile of American dividend payers (4.5%). Higher than average of industry peers (0.6%). New Risk • Aug 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (US$62k sold). Price Target Changed • Aug 06
Price target decreased by 13% to US$105 Down from US$120, the current price target is an average from 2 analysts. New target price is 69% above last closing price of US$62.01. Stock is down 48% over the past year. The company is forecast to post earnings per share of US$1.53 next year compared to a net loss per share of US$0.36 last year. Reported Earnings • Aug 05
First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2026 results: EPS: US$0.87 (up from US$0.63 in 1Q 2025). Revenue: US$59.5m (up 2.4% from 1Q 2025). Net income: US$4.74m (up 40% from 1Q 2025). Profit margin: 8.0% (up from 5.8% in 1Q 2025). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 95%. Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 37 percentage points per year, which is a significant difference in performance. Bekanntmachung • Jul 14
Mesa Laboratories, Inc., Annual General Meeting, Aug 22, 2025 Mesa Laboratories, Inc., Annual General Meeting, Aug 22, 2025. Location: mesa laboratories, lakewood, colorado 80228, United States Declared Dividend • Jul 06
Fourth quarter dividend of US$0.16 announced Dividend of US$0.16 is the same as last year. Ex-date: 29th August 2025 Payment date: 15th September 2025 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%. Bekanntmachung • Jul 04
Mesa Labs Declares Quarterly Dividend, Payable on September 15, 2025 Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025. Bekanntmachung • Jul 03
Mesa Laboratories, Inc. to Report Q1, 2026 Results on Aug 05, 2025 Mesa Laboratories, Inc. announced that they will report Q1, 2026 results at 8:00 AM, US Eastern Standard Time on Aug 05, 2025 Board Change • Jul 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Mark Capone was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions Derivative • Jun 18
CEO, President & Director notifies of intention to sell stock Gary Owens intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 16th of June. If the sale is conducted around the recent share price of US$97.12, it would amount to US$188k. For the year to March 2019, Gary's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2024, Gary's direct individual holding has increased from 36.85k shares to 43.34k. Company insiders have collectively sold US$897k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • May 29
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: US$0.36 loss per share (improved from US$47.21 loss in FY 2024). Revenue: US$241.0m (up 12% from FY 2024). Net loss: US$1.97m (loss narrowed 99% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 5.0% p.a. on average during the next 2 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance. Upcoming Dividend • May 23
Upcoming dividend of US$0.16 per share Eligible shareholders must have bought the stock before 30 May 2025. Payment date: 16 June 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.6%. Lower than top quartile of American dividend payers (4.8%). In line with average of industry peers (0.7%). Declared Dividend • Apr 14
Third quarter dividend of US$0.16 announced Dividend of US$0.16 is the same as last year. Ex-date: 30th May 2025 Payment date: 16th June 2025 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%. Bekanntmachung • Apr 08
Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 16, 2025 Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 16, 2025, to shareholders of record at the close of business on May 30, 2025. Recent Insider Transactions Derivative • Mar 20
CEO, President & Director notifies of intention to sell stock Gary Owens intends to sell 21k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of March. If the sale is conducted around the recent share price of US$124, it would amount to US$2.6m. For the year to March 2018, Gary's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2024, Gary's direct individual holding has decreased from 114.93k shares to 43.34k. Company insiders have collectively sold US$967k more than they bought, via options and on-market transactions in the last 12 months. Upcoming Dividend • Feb 21
Upcoming dividend of US$0.16 per share Eligible shareholders must have bought the stock before 28 February 2025. Payment date: 17 March 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.5%. Lower than top quartile of American dividend payers (4.5%). In line with average of industry peers (0.6%). Price Target Changed • Feb 07
Price target increased by 13% to US$150 Up from US$133, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of US$148. Stock is up 57% over the past year. The company is forecast to post earnings per share of US$1.15 next year compared to a net loss per share of US$47.20 last year. Reported Earnings • Feb 04
Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2025 results: US$0.31 loss per share (down from US$0.39 profit in 3Q 2024). Revenue: US$62.8m (up 18% from 3Q 2024). Net loss: US$1.68m (down 179% from profit in 3Q 2024). Revenue exceeded analyst estimates by 6.8%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance. Bekanntmachung • Jan 19
Mesa Laboratories, Inc. to Report Q3, 2025 Results on Feb 04, 2025 Mesa Laboratories, Inc. announced that they will report Q3, 2025 results at 8:00 AM, Eastern Standard Time on Feb 04, 2025 Declared Dividend • Jan 10
Second quarter dividend of US$0.16 announced Dividend of US$0.16 is the same as last year. Ex-date: 28th February 2025 Payment date: 17th March 2025 Dividend yield will be 0.5%, which is about the same as the industry average. Bekanntmachung • Jan 07
Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 17, 2025 Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025. Upcoming Dividend • Nov 22
Upcoming dividend of US$0.16 per share Eligible shareholders must have bought the stock before 29 November 2024. Payment date: 16 December 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.6%. Lower than top quartile of American dividend payers (4.3%). In line with average of industry peers (0.5%). Reported Earnings • Nov 08
Second quarter 2025 earnings: EPS exceeds analyst expectations Second quarter 2025 results: EPS: US$0.63 (up from US$0.23 loss in 2Q 2024). Revenue: US$57.8m (up 8.8% from 2Q 2024). Net income: US$3.43m (up US$4.66m from 2Q 2024). Profit margin: 5.9% (up from net loss in 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates significantly. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Nov 01
CEO, President & Director recently sold US$572k worth of stock On the 29th of October, Gary Owens sold around 5k shares on-market at roughly US$113 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Gary's only on-market trade for the last 12 months. Recent Insider Transactions Derivative • Oct 30
CEO, President & Director notifies of intention to sell stock Gary Owens intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of October. If the sale is conducted around the recent share price of US$114, it would amount to US$286k. For the year to March 2018, Gary's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2024, Gary's direct individual holding has decreased from 114.93k shares to 36.85k. Company insiders have collectively sold US$395k more than they bought, via options and on-market transactions in the last 12 months. Declared Dividend • Oct 06
First quarter dividend of US$0.16 announced Dividend of US$0.16 is the same as last year. Ex-date: 29th November 2024 Payment date: 16th December 2024 Dividend yield will be 0.5%, which is higher than the industry average of 0.4%. Bekanntmachung • Oct 03
Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 16, 2024 Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. Recent Insider Transactions Derivative • Sep 16
Insider notifies of intention to sell stock Brian Archbold intends to sell 1k shares in the next 90 days after lodging an Intent To Sell Form on the 13th of September. If the sale is conducted around the recent share price of US$125, it would amount to US$187k. Since December 2023, Brian's direct individual holding has increased from 558.00 shares to 1.50k. Company insiders have collectively sold US$395k more than they bought, via options and on-market transactions in the last 12 months. Price Target Changed • Sep 14
Price target increased by 10% to US$130 Up from US$118, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of US$126. Stock is up 2.3% over the past year. The company is forecast to post earnings per share of US$1.51 next year compared to a net loss per share of US$47.20 last year. Declared Dividend • Jul 29
Fourth quarter dividend of US$0.16 announced Dividend of US$0.16 is the same as last year. Ex-date: 30th August 2024 Payment date: 16th September 2024 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%. Bekanntmachung • Jul 22
Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024 Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024. Location: corporate headquarters at 12100 west sixth avenue, lakewood, colorado 80228., United States Bekanntmachung • Jul 09
Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on September 16, 2024 Mesa Laboratories, Inc. announced that its Board of Directors have declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 16, 2024, to shareholders of record at the close of business on August 30, 2024. Reported Earnings • Jun 06
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2024 results: US$47.21 loss per share (down from US$0.17 profit in FY 2023). Revenue: US$216.2m (down 1.3% from FY 2023). Net loss: US$254.2m (down US$255.2m from profit in FY 2023). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 133 percentage points per year, which is a significant difference in performance. Bekanntmachung • Jun 06
Mesa Laboratories, Inc. Reports Impairment of Goodwill and Long-Lived Assets for the Fourth Quarter Ended March 31, 2024 Mesa Laboratories, Inc. reported Impairment of goodwill and long-lived assets for the fourth quarter ended March 31, 2024 of $274,533,000. Upcoming Dividend • May 24
Upcoming dividend of US$0.16 per share Eligible shareholders must have bought the stock before 31 May 2024. Payment date: 14 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.6%. Lower than top quartile of American dividend payers (4.7%). Higher than average of industry peers (0.3%). Declared Dividend • Apr 08
Third quarter dividend of US$0.16 announced Dividend of US$0.16 is the same as last year. Ex-date: 31st May 2024 Payment date: 14th June 2024 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 363%. Cash payout ratio: 8%. Bekanntmachung • Apr 05
Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024 Mesa Laboratories, Inc. announced that its board of directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 14, 2024, to shareholders of record at the close of business on May 31, 2024. Bekanntmachung • Apr 02
Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024 Mesa Laboratories, Inc. announced that they will report Q4, 2024 results at 8:00 AM, US Eastern Standard Time on May 24, 2024 Major Estimate Revision • Mar 10
Consensus EPS estimates upgraded to US$0.055 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.08 to -US$0.055 per share. Revenue forecast steady at US$212.8m. Life Sciences industry in the US expected to see average net income growth of 12% next year. Consensus price target of US$127 unchanged from last update. Share price rose 2.3% to US$112 over the past week. Upcoming Dividend • Feb 21
Upcoming dividend of US$0.16 per share Eligible shareholders must have bought the stock before 28 February 2024. Payment date: 15 March 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.6%. Lower than top quartile of American dividend payers (4.7%). Higher than average of industry peers (0.4%). New Risk • Feb 07
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 154% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.3x net interest cover). Minor Risk Large one-off items impacting financial results. Reported Earnings • Feb 05
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2024 results: EPS: US$0.39 (up from US$0.084 in 3Q 2023). Revenue: US$53.5m (down 1.5% from 3Q 2023). Net income: US$2.12m (up 369% from 3Q 2023). Profit margin: 4.0% (up from 0.8% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) exceeded analyst estimates significantly. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings. Bekanntmachung • Jan 08
Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors Mesa Laboratories, Inc. announced the appointment of Mark Capone to its Board of Directors, effective January 5, 2024. Following Mr. Capone’s election, the Mesa Board will be comprised of 7 directors, the majority of whom are independent. The Board is committed to ongoing director refreshment and continues to consider new, qualified independent directors. Mr. Capone most recently served as CEO and President of Myriad Genetics for five years. Prior to his appointment as CEO and President, he held various progressive leadership roles at Myriad Genetics, with a total tenure of 17 years at the company. During his leadership tenure, he oversaw Myriad Genetics’ growth from an early-stage pioneer in molecular diagnostics into a leading global precision medicine company. Prior to his tenure at Myriad Genetics, Mr. Capone spent 17 years with Eli Lilly and Company in positions across the entire value chain. In addition to his executive leadership positions, Mr. Capone is a Non-Executive Director and member of the Compensation Committee for of Owlstone Medical Ltd, a breath biopsy diagnostic company focused on early detection of cancer and precision medicine, and a Non-Executive Director and member of the Audit Committee and Financing Committee of DermTech, a U.S. based company focused on early melanoma detection and other skin applications. Previously, Mr. Capone was a director at Abcam PLC, helping to guide that company through its acquisition by Danaher Corporation. Mr. Capone holds a Bachelor of Science in Chemical Engineering from Pennsylvania State University and a M.Sc. in Management and a M.Sc.in Chemical Engineering from Massachusetts Institute of Technology. Bekanntmachung • Jan 05
Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024 Mesa Laboratories, Inc. announced that on January 2, 2024 its Board of Directors declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2024, to shareholders of record at the close of business on February 29, 2024. Recent Insider Transactions Derivative • Dec 18
Insider notifies of intention to sell stock Brian Archbold intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of December. If the sale is conducted around the recent share price of US$116, it would amount to US$174k. Since June 2023, Brian has owned 9.65k shares directly. Company insiders have collectively sold US$1.5m more than they bought, via options and on-market transactions in the last 12 months. Bekanntmachung • Dec 15
Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024 Mesa Laboratories, Inc. announced that they will report Q3, 2024 results at 8:00 AM, US Eastern Standard Time on Feb 05, 2024 Upcoming Dividend • Nov 22
Upcoming dividend of US$0.16 per share at 0.7% yield Eligible shareholders must have bought the stock before 29 November 2023. Payment date: 15 December 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.7%. Lower than top quartile of American dividend payers (4.9%). Higher than average of industry peers (0.4%). Price Target Changed • Nov 09
Price target decreased by 17% to US$115 Down from US$139, the current price target is an average from 2 analysts. New target price is 23% above last closing price of US$93.73. Stock is down 45% over the past year. The company posted earnings per share of US$0.17 last year. Reported Earnings • Nov 07
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: US$0.23 loss per share (down from US$0.24 profit in 2Q 2023). Revenue: US$53.2m (down 9.5% from 2Q 2023). Net loss: US$1.23m (down 194% from profit in 2Q 2023). Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings. Bekanntmachung • Oct 18
Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million. Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million on October 16, 2023. The total purchase price for the acquisition of the entity along with other 2 entities is €85 million, subject to customary purchase price adjustments and holdbacks. Collectively the three entities are referred to as “GKE”. The transactions were or will be funded with proceeds from our credit facility and cash on hand. The transaction is subject to customary conditions, including receipt of applicable Chinese regulatory approvals and is expected to be completed during our third quarter ending December 31, 2023. Bekanntmachung • Oct 17
Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million. Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million on October 16, 2023. The consideration will be paid in cash and will be funded with proceeds from credit facility and cash on hand. In a related transaction Mesa Laboratories, Inc. (NasdaqGS:MLAB) will acquire Beijing GKE Science & Technology Co. LTD for €5 million.
Mesa Laboratories, Inc. (NasdaqGS:MLAB) completed the acquisition of Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH on October 16, 2023. Price Target Changed • Oct 05
Price target decreased by 8.9% to US$139 Down from US$153, the current price target is an average from 2 analysts. New target price is 40% above last closing price of US$98.95. Stock is down 31% over the past year. The company is forecast to post earnings per share of US$0.68 for next year compared to US$0.17 last year. 
